Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,193 | 825 | 99.8% |
| Education | $20.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $5,532 | 491 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,061 | 59 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $578.47 | 33 | $0 (2024) |
| Janssen Biotech, Inc. | $521.01 | 41 | $0 (2024) |
| Gilead Sciences, Inc. | $395.54 | 30 | $0 (2024) |
| Enterra Medical, Inc. | $389.08 | 3 | $0 (2024) |
| Nestle HealthCare Nutrition Inc. | $359.35 | 38 | $0 (2022) |
| IRONWOOD PHARMACEUTICALS, INC | $272.81 | 18 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $224.45 | 19 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $154.46 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,303 | 129 | ABBVIE INC. ($894.29) |
| 2023 | $1,746 | 97 | ABBVIE INC. ($782.27) |
| 2022 | $1,662 | 125 | ABBVIE INC. ($925.36) |
| 2021 | $1,455 | 113 | AbbVie Inc. ($732.96) |
| 2020 | $861.47 | 76 | AbbVie Inc. ($592.94) |
| 2019 | $1,344 | 113 | AbbVie, Inc. ($787.42) |
| 2018 | $1,054 | 97 | AbbVie, Inc. ($470.72) |
| 2017 | $785.69 | 76 | AbbVie, Inc. ($345.79) |
All Payment Transactions
826 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $3.47 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.03 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Immunology | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $0.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $8.88 | General |
| Category: VIROLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Immunology | ||||||
| 10/22/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.42 | General |
| Category: Immunology | ||||||
| 10/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $27.27 | General |
| Category: Gastroenterology | ||||||
| 10/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.42 | General |
| 10/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $6.35 | General |
| Category: Gastroenterology | ||||||
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $0.32 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 457 | 479 | $294,709 | $52,386 |
| 2022 | 18 | 783 | 828 | $435,604 | $75,879 |
| 2021 | 19 | 926 | 1,037 | $443,262 | $89,019 |
| 2020 | 20 | 808 | 909 | $374,819 | $75,905 |
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 70 | 70 | $81,877 | $13,294 | 16.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 47 | 47 | $38,916 | $8,042 | 20.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 67 | 72 | $47,304 | $4,934 | 10.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 45 | 45 | $14,175 | $4,896 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 48 | $9,888 | $4,073 | 41.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 35 | 35 | $34,615 | $2,952 | 8.5% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 24 | 26 | $19,240 | $2,734 | 14.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 41 | $5,699 | $2,576 | 45.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 15 | 15 | $12,113 | $2,569 | 21.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $4,914 | $1,344 | 27.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $9,108 | $1,300 | 14.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $3,502 | $1,263 | 36.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 21 | $3,906 | $1,224 | 31.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $9,452 | $1,188 | 12.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 114 | 114 | $133,836 | $21,294 | 15.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 49 | 49 | $40,572 | $8,218 | 20.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 102 | 104 | $68,328 | $6,016 | 8.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 56 | 69 | $14,214 | $5,624 | 39.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 52 | 52 | $16,380 | $5,277 | 32.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 42 | 44 | $12,894 | $4,300 | 33.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 24 | 24 | $19,565 | $3,877 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 65 | 65 | $9,035 | $3,474 | 38.5% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 31 | 34 | $22,435 | $3,102 | 13.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 40 | 40 | $39,560 | $2,720 | 6.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 45 | 57 | $8,667 | $2,711 | 31.3% |
About Dr. Andrew Katz, MD
Dr. Andrew Katz, MD is a Gastroenterology healthcare provider based in Fort Wayne, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548237951.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Katz, MD has received a total of $11,213 in payments from pharmaceutical and medical device companies, with $2,303 received in 2024. These payments were reported across 826 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($11,193).
As a Medicare-enrolled provider, Katz has provided services to 2,974 Medicare beneficiaries, totaling 3,253 services with total Medicare billing of $293,189. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Fort Wayne, IN
- Active Since 03/03/2006
- Last Updated 09/29/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1548237951
Products in Payments
- LINZESS (Drug) $1,216
- Humira (Biological) $681.40
- RINVOQ (Biological) $642.33
- SKYRIZI (Biological) $545.72
- HUMIRA (Biological) $539.99
- ENTYVIO (Biological) $513.76
- MAVYRET (Drug) $498.26
- ZENPEP (Drug) $434.56
- STELARA (Biological) $395.76
- Entyvio (Biological) $377.80
- XIFAXAN (Drug) $374.95
- Creon (Drug) $351.06
- CREON (Drug) $331.75
- DUPIXENT (Biological) $266.35
- Mavyret (Drug) $241.79
- Linzess (Drug) $234.41
- Trulance (Drug) $224.45
- TRULANCE (Drug) $188.52
- OMVOH (Drug) $152.39
- VIBERZI (Drug) $144.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Fort Wayne
Dr. Efesomwan Aisien, M.d, M.D
Gastroenterology — Payments: $89,557
Dr. Abdo Saad, Md, MD
Gastroenterology — Payments: $59,492
Melissa Garrett, Md, MD
Gastroenterology — Payments: $59,090
Dr. Mariajose Rojas De Leon, Md, MD
Gastroenterology — Payments: $39,782
Dr. Kirsten Weiser, M.d, M.D
Gastroenterology — Payments: $20,935
Dr. David Gutman, Md, Facg, MD, FACG
Gastroenterology — Payments: $13,732